Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.24 USD
Change Today -0.005 / -2.02%
Volume 41.0K
NUOT On Other Exchanges
As of 8:10 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

nuo therapeutics inc (NUOT) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/22/14 - $0.67
52 Week Low
03/18/15 - $0.17
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NUO THERAPEUTICS INC (NUOT)

Related News

No related news articles were found.

nuo therapeutics inc (NUOT) Related Businessweek News

No Related Businessweek News Found

nuo therapeutics inc (NUOT) Details

Nuo Therapeutics, Inc., a biomedical company, provides biodynamic therapies for wound care. Its flagship product is the Aurix, a biodynamic hematogel that harnesses a patient's innate regenerative abilities for the management of various wounds. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was founded in 1987 and is based in Gaithersburg, Maryland.

40 Employees
Last Reported Date: 07/10/14
Founded in 1987

nuo therapeutics inc (NUOT) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $467.3K
Executive Chairman
Total Annual Compensation: $100.0K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $185.3K
Compensation as of Fiscal Year 2013.

nuo therapeutics inc (NUOT) Key Developments

Nuo Therapeutics, Inc. Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 08:55 AM

Nuo Therapeutics, Inc. Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 08:55 AM. Venue: Metropolitan Club, One East 60th Street, New York, NY 10022, United States. Speakers: Brian Abraham, Senior Director, Market Access & Reimbursement.

Nuo Therapeutics, Inc. Initiates Phase 4 Study of Aurix Under CMS Coverage with Evidence Development Program

Nuo Therapeutics, Inc. announced the initiation of a new clinical study (Au Study) that is comprised of three randomized controlled protocols that examine the efficacy of Aurix, a biodynamic hematogel, for use in diabetic foot ulcers, venous leg ulcers and pressure ulcers (bed sores). The aim of this study is to demonstrate the effectiveness of complete wound healing in three prospective, open-label, randomized studies in which diabetic foot ulcers, venous leg ulcers and pressure ulcers, respectively, will be treated using Aurix and standard care, and compared one-to-one with patients receiving Usual and Customary Care. The Centers for Medicare and Medicaid Services has approved these amended protocols under its Coverage with Evidence Development Program to address coverage of items and services that require additional evidence of the clinical and economic impact on Medicare beneficiary health outcomes. Under this program, CMS will reimburse for Aurix when health care providers agree to collect their Medicare patients' treatment data for inclusion in the study database. The Au Study is an evolution of the Aurix Data Collection program that, with implementation of these amended protocols to include diabetic foot ulcers, venous leg ulcers and pressure ulcers, may integrate into current physician practice operations and broaden valuable inclusion criteria, allowing for greater patient access to the Aurix System in centers across the U.S.

Nuo Therapeutics, Inc. Enters into Distributor Agreement and License with Rohto Pharmaceutical Co., Ltd

On January 6, 2015, Nuo Therapeutics, Inc. entered into Distributor Agreement and License with Rohto Pharmaceutical Co. Ltd. Under the terms of the Rhoto Agreement, the company granted to Rohto a royalty bearing, nontransferable, exclusive license, with limited right to sublicense, to use certain of the company’s intellectual property for the development, import, use, manufacturing, marketing, sale and distribution for all wound care and topical dermatology applications of the Aurix system and related intellectual property and know-how in human and veterinary medicine in Japan, in exchange for an upfront payment to the company of USD 3 million. The Rohto Agreement also contemplates a milestone payment of USD 1 million in the event the reimbursement price for the product in Japan is achieved in the future, and future royalty payments based upon net sales of such systems in Japan. Rohto agreed to conduct required clinical and other studies for the marketing authorization with Japan’s Ministry of Health, Labour and Welfare at its own expense, including submission of the marketing authorization application with such regulatory agency. In the event the company determines to seek distribution in other Eastern and South Eastern Asian countries, the parties agreed to negotiate in good faith such potential distribution arrangement. The initial term of the Rohto Agreement is fifteen years, which term is automatically renewable for an additional one-year period unless terminated by either party to the agreement. The Rohto Agreement contains other terms and provisions that are customary to agreements of this nature.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NUOT:US $0.24 USD -0.005

NUOT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioheart Inc $0.01 USD +0.0005
Cesca Therapeutics Inc $0.81 USD +0.0039
Cytori Therapeutics Inc $1.18 USD -0.01
International Stem Cell Corp $0.06 USD +0.0004
StemCells Inc $0.98 USD -0.005
View Industry Companies

Industry Analysis


Industry Average

Valuation NUOT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.3x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUO THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at